Leuchtenberger takes reins at Rib-X

Mark Leuchtenberger, who tried, and failed, to develop an antibiotic at Targanta, is getting another crack at the same target. Leuchtenberger has been hired to take over as CEO of Rib-X in New Haven, CT. Founder Susan Froshauer will retain her title as CSO. Leuchtenberger sold Targanta to The Medicines Company in early 2009 after the FDA rejected the company's application for its lead antibiotic, oritavancin, and forced the developer to lay off 75 percent of its staff. Release | Report

Suggested Articles

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.